Synthesis, in vitro and in silico studies on novel 3-aryloxymethyl-5-[(2-oxo-2-arylethyl)sulfanyl]-1,2,4-triazoles and their oxime derivatives as potent inhibitors of mPGES-1

Autor: Gizem Erensoy, Kai Ding, Chang-Guo Zhan, Gamze Çiftçi, Kemal Yelekçi, Merve Duracık, Özlem Bingöl Özakpınar, Esra Aydemir, Zübeyde Nur Yılmaz, Fikrettin Şahin, Necla Kulabaş, Esra Tatar, İlkay Küçükgüzel
Přispěvatelé: Mühendislik ve Doğa Bilimleri Fakültesi, Erensoy G., Ding K., Zhan C., Çiftçi G., Yelekçi K., Duracık M., Bingöl Özakpınar Ö., Aydemir E., Yılmaz Z. N. , Şahin F., et al.
Rok vydání: 2023
Předmět:
Farmasötik Kimya
Farmakoloji
Life Sciences (LIFE)
Pharmacy
Sağlık Bilimleri
Clinical Medicine (MED)
Analytical Chemistry
Pharmaceutical Chemistry
Inorganic Chemistry
Meslek Bilimleri
Drug Guides
Health Sciences
Yaşam Bilimleri
4-triazoles
Professional Sciences
FARMAKOLOJİ VE ECZACILIK
Klinik Tıp (MED)
Farmakoloji
Toksikoloji ve Eczacılık (çeşitli)
Pharmacology (medical)
General Pharmacology
Toxicology and Pharmaceutics
Eczacılık
PHARMACOLOGY & PHARMACY
Pharmacology
Toxicology and Pharmaceutics (miscellaneous)
Spectroscopy
Cancer
Pharmacology
Inflammation
PHARMACOLOGY & TOXICOLOGY
Organic Chemistry
Life Sciences
mPGES-1
Pharmacology and Therapeutics
Genel Farmakoloji
Toksikoloji ve Eczacılık
Farmakoloji (tıbbi)
Molecular Docking
İlaç Rehberleri
Yaşam Bilimleri (LIFE)
Farmakoloji ve Toksikoloji
Angiogenesis
1
2
4-Triazoles
Zdroj: Journal of Molecular Structure. 1272:134154
ISSN: 0022-2860
DOI: 10.1016/j.molstruc.2022.134154
Popis: Human microsomal prostaglandin E synthase (mPGES)-1 is a glutathione-dependent membrane-bound enzyme which is involved in the terminal stage of prostaglandin E2 (PGE2) synthesis. It has been well reported as a key target for the discovery of new anti-inflammatory and anti-cancer drugs. Specific in- hibitors of mPGES-1 are anticipated to selectively restrain the generation of PGE2 induced by the in- flammatory stimuli, without obstructing of the regular biosynthesis of other homeostatic prostanoids. Therefore, the design of mPGES-1 inhibitors can represent a better choice to take control of PGE2 asso- ciated diseases, compared with conventional non-steroidal anti-inflammatory drugs and cyclooxygenase (COX) inhibitors, which are known for their serious side effects. Although there is an intensive effort for the identification of mPGES-1 inhibitors, none of the unveiled molecules so far have reached the clini- cal market. Therefore, the development of novel mPGES-1 inhibitors with proper drug-like properties is still an unmet medical need. As a continuation of our research for the identification of new chemotypes which might inhibit this enzyme, we now report the design and synthesis of 3-aryloxymethyl-5-[(2-oxo- 2-arylethyl)sulfanyl]-1,2,4-triazoles and their oxime derivatives as inhibitors of human mPGES-1. All syn- thesized compounds were characterized by FTIR, 1H NMR, 13C NMR (for compounds 12, 14, 15, 26, 27), HMBC (for compounds 6, 7, 8, 16, 19, 23, 28), and MS data. Twenty-four target compounds 7–30 were screened for their mPGES-1/COX-2 inhibitory activities as well as their cytotoxicity. Of these compounds, 20 and 24 showed potent mPGES-1 inhibition by IC50 values of 0.224±0.070 μM and 1.08±0.35 μM, re- spectively. These two compounds have also been observed to inhibit angiogenesis in matrigel tube forma- tion assay with no toxicity toward HUVEC cells. In silico studies were also held to understand inhibition mechanisms of the most active compounds using molecular docking, molecular dynamics calculations and ADMET predictions.
Databáze: OpenAIRE
Externí odkaz: